PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

被引:50
|
作者
Irwin, Christopher P. [1 ]
Portorreal, Yasiri [1 ]
Brand, Christian [1 ]
Zhang, Yachao [1 ]
Desai, Pooja [1 ]
Salinas, Beatriz [1 ]
Weber, Wolfgang A. [2 ,3 ]
Reiner, Thomas [1 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Radiochem & Imaging Sci Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Imaging & Nanotechnol, New York, NY 10065 USA
来源
NEOPLASIA | 2014年 / 16卷 / 05期
关键词
RESECTION; SURVIVAL; GLIOMA; EXTENT; EXPRESSION; OLAPARIB; GUIDANCE; SURGERY;
D O I
10.1016/j.neo.2014.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression. Importantly, subcutaneous and orthotopic glioblastoma xenografts were imaged with high contrast clearly defining tumor tissue from normal surrounding tissue. This research represents a step toward exploring and developing PARPi-FL as an optical intraoperative imaging agent for PARP1 in the clinic.
引用
收藏
页码:432 / 440
页数:9
相关论文
共 50 条
  • [31] BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments
    Lahiri, Sudipta
    Hamilton, George
    Moore, Gemma
    Goehring, Liana
    Huang, Tony T.
    Jensen, Ryan B.
    Rothenberg, Eli
    NATURE, 2025,
  • [32] PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma
    Murnyak, Balazs
    Kouhsari, Mahan C.
    Hershkovitch, Rotem
    Kalman, Bernadette
    Marko-Varga, Gyorgy
    Klekner, Almos
    Hortobagyi, Tibor
    ONCOTARGET, 2017, 8 (28) : 46348 - 46362
  • [33] HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
    Ma, Hanlin
    Qi, Gonghua
    Han, Fang
    Lu, Wei
    Peng, Jiali
    Li, Rongrong
    Yan, Shi
    Yuan, Cunzhong
    Kong, Beihua
    CELL DEATH & DISEASE, 2022, 13 (03)
  • [34] FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance
    Chen, MeiKuang
    Gao, Yuan
    Xia, Weiya
    Wang, Yu-Han
    Litton, Jennifer K.
    Chu, Yu-Yi
    Meric-Bernstam, Funda
    Piwnica-Worms, Helen
    Arun, Banu
    Ahnert, Jordi Rodon
    Wei, Yongkun
    Chang, Wei-Chao
    Wang, Hung-Ling
    Tapia, Coya
    Albarracin, Constance T.
    Wang, Shao-Chun
    Wang, Ying-Nai
    Hortobagyi, Gabriel N.
    Lin, Chunru
    Yang, Liuqing
    Yu, Dihua
    Hung, Mien-Chie
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression
    Sun, Zeren
    Li, Lanjie
    Zhai, Bingxin
    Hu, Mengxuan
    Huang, Lei
    Huang, Shihui
    Ye, Liu
    Kong, Xiangying
    Xu, Jie
    Bai, Jie
    Yan, Jingjie
    Zhou, Qichen
    Hu, Zheqi
    Zhang, Yuchen
    Jiang, Yuhan
    Zhang, Yan
    Qiao, Zhou
    Zou, Yi
    Xu, Yungen
    Zhu, Qihua
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (06) : 4916 - 4935
  • [36] PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
    Froehlich, Lisa Marie
    Villar-Miyar, Ana
    Heintze, Tamara
    Sauer, Birgit
    Schittek, Birgit
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (02) : 203 - 210
  • [37] The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
    Gatti, Marco
    Imhof, Ralph
    Huang, Qingyao
    Baudis, Michael
    Altmeyer, Matthias
    CELL REPORTS, 2020, 32 (05):
  • [38] HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
    Hanlin Ma
    Gonghua Qi
    Fang Han
    Wei Lu
    Jiali Peng
    Rongrong Li
    Shi Yan
    Cunzhong Yuan
    Beihua Kong
    Cell Death & Disease, 13
  • [39] Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
    Ryan K.
    Bolaños B.
    Smith M.
    Palde P.B.
    Cuenca P.D.
    VanArsdale T.L.
    Niessen S.
    Zhang L.
    Behenna D.
    Ornelas M.A.
    Tran K.T.
    Kaiser S.
    Lum L.
    Stewart A.
    Gajiwala K.S.
    Journal of Biological Chemistry, 2021, 296
  • [40] Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
    Ryan, Kevin
    Bolanos, Ben
    Smith, Marissa
    Palde, Prakash B.
    Cuenca, Paulina Delgado
    VanArsdale, Todd L.
    Niessen, Sherry
    Zhang, Lianglin
    Behenna, Douglas
    Ornelas, Martha A.
    Tran, Khanh T.
    Kaiser, Stephen
    Lum, Lawrence
    Stewart, Al
    Gajiwala, Ketan S.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296